Treatments that remove or neutralize anti-AQP4 antibodies (such as aquaporumab or monoclonal antibodies like eculizumab) markedly improve NMO, reinforcing how critical AQP4 is to CNS homeostasis [53,54]. Here, AQP4 is linked to neuromyelitis optica.